American Journal of Kidney Diseases
Volume 50, Issue 4 , Pages 602-611 , October 2007

Aspirin Prescription and Outcomes in Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

  • Jean Éthier, MD

      Affiliations

    • Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada
    • Corresponding Author InformationAddress correspondence to Jean Éthier, MD, Centre Hospitalier de l’Université de Montréal, Hôtel Dieu de Montréal, 3840, rue Saint-Urbain, Montreal, Québec H2W 1T8 Canada.
    • ,
  • Jennifer L. Bragg-Gresham, MS

      Affiliations

    • Arbor Research Collaborative for Health, Ann Arbor, MI
    • ,
  • Luis Piera, MD

      Affiliations

    • Hospital General Vall D’Hebron, Barcelona, Spain
    • ,
  • Tadao Akizawa, MD

      Affiliations

    • Department of Nephrology, Showa University School of Medicine, Tokyo, Japan
    • ,
  • Yasushi Asano, MD, PhD

      Affiliations

    • Koga Red Cross Hospital, Ibaraki, Japan
    • ,
  • Nancy Mason, PharmD

      Affiliations

    • University of Michigan, School of Pharmacology, Ann Arbor, MI
    • Nephrology Pharmacy Associates, Ann Arbor, MI
    • ,
  • Brenda W. Gillespie, PhD

      Affiliations

    • Department of Biostatistics, University of Michigan, Ann Arbor, MI
    • ,
  • Eric W. Young, MD, MS

      Affiliations

    • Veterans Affairs Medical Center/University of Michigan, Ann Arbor, MI.

Received 1 February 2007 ,Accepted 5 July 2007.

References 

  1. US Renal Data System. USRDS 2003 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003;
  2. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799–805
  3. Townsend RR. Cardiac mortality in chronic kidney disease: A clearer perspective. Ann Intern Med. 2002;137:615–616
  4. Antiplatelet Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  5. Eidelman RS, Hebert PR, Weisman SE, Hennekens GH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:2006–2010
  6. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85:265–271
  7. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–313
  8. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–1304
  9. Zanchetti A, Hansson L, Dahlöf B, et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens. 2002;20:2301–2307
  10. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853–906
  11. Young EW, Goodkin DA, Mapes DL, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney Int Suppl. 2000;74:S74–S81
  12. Pisoni RL, Gillespie BW, Dickinson DM, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): Design, data elements, and methodology. Am J Kidney Dis. 2004;44(suppl 2):S7–S15
  13. SAS Technical Support: GLIMMIX: A SAS Macro for Fitting Generalized Linear Mixed Models Using Proc Mixed and the Output Delivery System (ODS). Available at: http://ftp.sas.com/techsup/download/stat/glmm800.html. Accessed August 30, 2004
  14. SAS Institute: SAS/STAT User’s Guide, version 8, vol 2. Cary, NC, SAS Institute, 1999, p 1452
  15. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. In: New York, NY: Springer; 1997;p. 416–418
  16. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med. 2002;137:563–570
  17. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137:555–562
  18. Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation. 2000;101:1097–1101
  19. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: Missed opportunities for prevention?. Arch Intern Med. 1999;159:561–567
  20. Beaulieu MD, Blais R, Jacques A, Battista RN, Lebeau R, Brophy J. Are patients suffering from stable angina receiving optimal medical treatment?. QJM. 2001;94:301–308
  21. Brown JB, Delea TE, Nichols GA, Edelsberg J, Elmer PJ, Oster G. Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease. Arch Intern Med. 2002;162:193–199
  22. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice. BMJ. 1998;316:1430–1434
  23. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37:484–489
  24. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J. 2002;144:226–232
  25. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201–208
  26. Conti CR. Management of patients with acute myocardial infarction and end-stage renal disease. J Am Coll Cardiol. 2003;42:209–210
  27. American Diabetes Association. Aspirin therapy in diabetes (position statement). Diabetes Care. 1997;20:1772–1773
  28. American Diabetes Association. Aspirin therapy in diabetes (position statement). Diabetes Care. 2000;23(suppl 1):S61–S62
  29. Reddan DN. Therapy for cardiovascular disease in patients with chronic kidney disease: Appropriate caution or the absence of data. Am Heart J. 2002;144:206–207
  30. Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G. Moderate doses of aspirin and risk of bleeding in renal failure. Lancet. 1986;1(8478):414–416
  31. Kaufman JS. Antithrombotic agents and the prevention of access thrombosis. Semin Dial. 2000;13:40–46
  32. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus (Early Treatment Diabetic Retinopathy Study report 14). JAMA. 1992;268:1292–1300
  33. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197–2202
  34. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int. 1994;45:1477–1483
  35. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2002;40:1255–1263
  36. Shahar E, Folsom AR, Romm FJ, et al. Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1996;131:915–922
  37. Andreucci VE, Fissell RB, Bragg-Gresham JL, et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis. 2004;44(suppl 2):S61–S67
  38. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  39. Saran R, Canaud BJ, Depner TA, et al. Dose of dialysis: Key lessons from major observational studies and clinical trials. Am J Kidney Dis. 2004;44(suppl 2):S47–S53
  40. Eknoyan G, Beck GJ, Cheung AK, et al. The Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  41. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:94–111
  42. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  43. Weigert AL, Schafer AI. Uremic bleeding: Pathogenesis and therapy. Am J Med Sci. 1998;316:94–104
  44. Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia (Multifaceted defect partially corrected by dialysis). Am J Med. 1985;79:552–559
  45. Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest. 1987;79:1788–1797
  46. Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, Vigano G. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest. 1990;86:1768–1771
  47. Diaz-Ricart M, Etebanell E, Cases A, et al. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost. 1999;82:1312–1317
  48. Zhou XJ, Vaziri ND. Defective calcium signalling in uraemic platelets and its amelioration with long-term erythropoietin therapy. Nephrol Dial Transplant. 2002;17:992–997
  49. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793–798
  50. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  51. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655

 Originally published online as doi:10.1053/j.ajkd.2007.07.007 on September 4, 2007.

PII: S0272-6386(07)01036-0

doi: 10.1053/j.ajkd.2007.07.007

American Journal of Kidney Diseases
Volume 50, Issue 4 , Pages 602-611 , October 2007

Article Tools

* Image Usage & Resolution